| Literature DB >> 28153057 |
Masahiko Kaneko1, Masaki Maruta2, Hisaharu Shikata2, Kengo Asou3, Hiroto Shinomiya4, Tadaki Suzuki5, Hideki Hasegawa5, Masayuki Shimojima6, Masayuki Saijo6.
Abstract
BACKGROUND: Severe fever with thrombocytopenia syndrome is an emerging infectious disease caused by a novel phlebovirus belonging to the family Bunyaviridate. Emergence of encephalitis/encephalopathy during severe fever with thrombocytopenia syndrome progression has been identified as a major risk factor associated with a poor prognosis. Here we report the case of a severely ill patient with severe fever with thrombocytopenia syndrome virus-associated encephalitis/encephalopathy characterized by a lesion of the splenium, which resolved later. CASEEntities:
Keywords: Case report; Encephalitis/encephalopathy; Reversible splenial lesion syndrome; Serum viral load; Severe fever with thrombocytopenia syndrome
Mesh:
Year: 2017 PMID: 28153057 PMCID: PMC5290612 DOI: 10.1186/s13256-016-1192-0
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Fig. 1T2- and diffusion-weighted images. T2-weighted (a) and diffusion-weighted (b) brain magnetic resonance images on the 2nd day showing high-intensity lesions in the splenium of the corpus callosum (arrow). The splenial lesions had completely disappeared on the 5th day (c)
Fig. 2Change in the severe fever with thrombocytopenia syndrome viral copy numbers in the serum of the present patient. The viral copy number on the 1st day after the onset of illness was 2.8 × 105 copies/mL and then rapidly decreased during the remaining period of hospitalization. The horizontal dashed line indicates the median detection limit for the quantitative reverse-transcription polymerase chain reaction assays (0.43 × 103 copies/mL). RNA, ribonucleic acid
Fig. 3Microscopic findings under May-Giemsa staining. Hemophagocytosis is present in the bone marrow (×1000)
Laboratory findings of the presented case of severe fever with thrombocytopenia syndrome (SFTS)
| Laboratory findings | Reference range | Days after illness onset | ||||||
|---|---|---|---|---|---|---|---|---|
| 2 | 3 | 5 | 6 | 9 | 15 | 19 | ||
| WBC (×109/L) | 4.0–9.0 | 1.4 | 2.8 | 2.63 | 3.19 | 4.36 | 5.95 | 6 |
| Hemoglobin (g/dL) | 12–16 (men) | 15.3 | 14.7 | 16.4 | 16.4 | 11.4 | 11.6 | 10.7 |
| Platelets (×109/L) | 150–450 | 86 | 59 | 31 | 17 | 30 | 205 | 342 |
| AST (U/L) | 13–33 | 145 | 159 | 628 | 362 | 131 | 40 | 28 |
| ALT (U/L) | 8–42 | 55 | 59 | 125 | 93 | 96 | 44 | 27 |
| LDH (U/L) | 100–200 | 360 | 429 | 1611 | 1128 | 472 | 326 | 189 |
| Amylase (U/L) | 33–120 | NA | 116 | 279 | 314 | 179 | 107 | 107 |
| Lipase (U/L) | 13–49 | NA | NA | 421 | 896 | 297 | 117 | 117 |
| CRP (mg/dL) | 0–0.3 | NA | 1.51 | 6.09 | NA | NA | 1.21 | NA |
| Creatinine (mg/dL) | 0.36–1.06 | 1.29 | 1.21 | 1.35 | 1.14 | 0.69 | 0.71 | 0.71 |
| CK (U/L) | 62–287 | 2276 | 2559 | 4016 | 4912 | 699 | 113 | 65 |
| CK-MB (U/L) | 0–24 | NA | 37 | 69 | NA | NA | NA | NA |
| Ferritin (U/mL) | 122–496 | NA | 1980 | 24667 | NA | 2209 | 413 | 413 |
| Sodium (mmol/L) | 135–149 | 125 | 129 | 137 | 143 | 137 | NA | 140 |
| PT/INR | 0.8–1.3 | 1.09 | 0.95 | 1.08 | NA | NA | NA | 0.91 |
| aPTT (s) | 24–36 | 59.1 | 40.9 | 100 | NA | NA | 32.6 | 32.6 |
| FDP (μg/mL) | 0–5 | NA | NA | 40.5 | NA | 2.5 | NA | 3.1 |
| D-dimer (μg/mL) | 0–1 | NA | 2.9 | 15.6 | NA | NA | NA | 2.3 |
| Urine protein (mg/day) | 684 | NA | 3845 | 3260 | 53163 | 813 | 685 | |
NA not available, WBC white blood cells, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, CRP C-reactive protein, CK creatine kinase, PT/INR prothrombin time/international normalized ratio, aPTT activated partial thromboplastin time, FDP fibrin/fibrinogen degradation products